Esperion Therapeutics ^{Priced, Nasdaq: ESPR}

Developing a treatment for elevated levels of low-density lipoprotein cholesterol.

Industry: Health Care

First Day Return: +3.6%

ESPR

Developing a treatment for elevated levels of low-density lipoprotein cholesterol.

IPO News for Esperion Therapeutics

US IPO Recap: Market picks up the pace with ten IPOs, six price below the range 07/01/13
Esperion Therapeutics prices upsized IPO at $14, the midpoint of the range 06/26/13
US IPO Recap: Coty fades, Gigamon springs and 17 companies file or set terms 06/17/13

IPO Data
IPO Date	06/25/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$70
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Plymouth, MI, United States
Founded	1998
Employees at IPO	13
Website www.esperion.com

IPO News for Esperion Therapeutics

Esperion Therapeutics (ESPR) Performance